These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28760882)

  • 21. T cells from a high proportion of apparently naive cattle can be activated by modified vaccinia virus Ankara (MVA).
    Sandbulte MR; Platt R; Roth JA
    Viral Immunol; 2004; 17(1):39-49. PubMed ID: 15018661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
    Viner KM; Girgis N; Kwak H; Isaacs SN
    Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
    Peacock JW; Nordone SK; Jackson SS; Liao HX; Letvin NL; Yafal AG; Gritz L; Mazzara GP; Haynes BF; Staats HF
    J Virol; 2004 Dec; 78(23):13163-72. PubMed ID: 15542668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
    Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
    J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells.
    Zimmerling S; Waibler Z; Resch T; Sutter G; Schwantes A
    Virol J; 2013 Jan; 10():34. PubMed ID: 23356675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
    Mullin J; Ahmed MS; Sharma R; Upile N; Beer H; Achar P; Puksuriwong S; Ferrara F; Temperton N; McNamara P; Lambe T; Gilbert SC; Zhang Q
    Vaccine; 2016 Mar; 34(14):1688-95. PubMed ID: 26902548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals.
    Leite Pereira A; Jouhault Q; Marcos Lopez E; Cosma A; Lambotte O; Le Grand R; Lehmann MH; Tchitchek N
    Front Immunol; 2020; 11():2096. PubMed ID: 33013882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.
    Abadie V; Bonduelle O; Duffy D; Parizot C; Verrier B; Combadière B
    PLoS One; 2009 Dec; 4(12):e8159. PubMed ID: 19997562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity.
    Blok BA; Jensen KJ; Aaby P; Fomsgaard A; van Crevel R; Benn CS; Netea MG
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):449-456. PubMed ID: 30719592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.
    Pavot V; Sebastian S; Turner AV; Matthews J; Gilbert SC
    Methods Mol Biol; 2017; 1581():97-119. PubMed ID: 28374245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study.
    Sanchez J; Gonçalves E; Llano A; Gonzáles P; Fernández-Maldonado M; Vogt A; Soria A; Perez S; Cedeño S; Fernández MA; Nourikyan J; de Bernard S; Ganoza C; Pedruzzi E; Bonduelle O; Mothe B; Gòmez CE; Esteban M; Garcia F; Lama JR; Brander C; Combadiere B
    Front Immunol; 2020; 11():586124. PubMed ID: 33244316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.
    Perrin LH; Zinkernagel RM; Oldstone MB
    J Exp Med; 1977 Oct; 146(4):949-69. PubMed ID: 302316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.